This week, four Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Pfizer (NYSE:PFE) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Pfizer is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. In Portfolio Grader’s specific subcategory of Earnings Momentum, PFE also gets an A. The stock price has risen 6.4% over the past month, better than the 2.4% increase the S&P 500 has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PFE stock.
Novartis (NYSE:NVS) gets a higher grade this week, advancing from a B last week to an A. Novartis manufactures pharmaceutical and consumer healthcare products. Wall Street has pushed the stock higher by 7.1% over the past month. The stock has a dividend yield of 2.5%. For more information, get Portfolio Grader’s complete analysis of NVS stock.
Watson Pharmaceuticals (NYSE:WPI) is seeing ratings go up from a B last week to an A this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This is a strong week for Mylan (NASDAQ:MYL). The company’s rating climbs to A from the previous week’s B. Mylan is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.